Filing Flows › Aurinia Pharmaceuticals (AUPH) › Q2 2025
Aurinia Pharmaceuticals (AUPH) Q2 2025 earnings results (second quarter 2025)
10-Q filed Jul 31, 2025
Aurinia Pharmaceuticals (AUPH) reported revenue of $70.0M for the second quarter 2025 (Q2 2025), +22% from a year earlier and +12% from the quarter before. Operating margin was 28.7%, net earnings $21.5M (30.7% of revenue).
Aurinia Pharmaceuticals, Q2 2025: revenue $70.0M (+22% year over year), operating margin 28.7%, net earnings $21.5M, operating cash flow $44.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $70.0M | +12% | +22% |
| Operating profit | $20.1M | -8% | — |
| Net earnings | $21.5M | -8% | 30× |
| Operating cash flow | $44.2M | 34× | +179% |
What changed
Revenue was $70.0M in Q2 2025, up 22% year over year and up 12% from the previous quarter. Net product sales was the largest line at 95% of revenue. Net product sales added $11.5M year over year (up 21%), 90% of the total change.
Operating profit was $20.1M, a 28.7% margin (up 31.3 points year over year). Total costs fell 15% while revenue rose 22%. The fastest-growing cost line was Other operating costs (+1097%). Net earnings were $21.5M, up 2880% year over year. The effective tax rate was 2.9%.
Operating cash flow was $44.2M (up 179% year over year), 206% of net earnings. Non-cash charges added back $4.9M of depreciation and amortization and $5.4M of share-based compensation. Working capital and other items added $12.4M.
Questions
What was Aurinia Pharmaceuticals' revenue in the second quarter 2025?
Aurinia Pharmaceuticals (AUPH) reported revenue of $70.0M for the second quarter 2025 (Q2 2025), +22% from a year earlier and +12% from the quarter before.
Was Aurinia Pharmaceuticals profitable in the second quarter 2025?
Operating profit was $20.1M (28.7% of revenue) and net earnings $21.5M.